

Georg A Bjarnason

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/910943/georg-a-bjarnason-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236
papers

12,844
citations

55
h-index

111
g-index

255
ext. papers

14,723
ext. citations

4.9
avg, IF

5.82
L-index

#	Paper	IF	Citations
236	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100899	3.3	0
235	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS398-TPS398	2.2	3
234	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 304-304	2.2	
233	Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 338-338	2.2	
232	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022 , 6, 69-79	0.6	
231	The future of precise cancer chronotherapeutics. <i>Lancet Oncology</i> , 2022 , 23, e242	21.7	0
230	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2021 , 15, 132-137	1.2	1
229	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1029-1039	2.2	43
228	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2021 , 15, 84-97	1.2	1
227	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021 , 5, 21-29	0.6	0
226	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. <i>Société Internationale Durologie Journal</i> , 2021 , 2, 82-95	0.1	
225	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1020-1028	2.2	26
224	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021 , 31, 215-220	1.9	1
223	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 820-826	3.6	6
222	Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 764-774	4	3
221	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 102-111	6.7	15
220	Local control and patterns of failure for "Radioresistant" spinal metastases following stereotactic body radiotherapy compared to a "Radiosensitive" reference. <i>Journal of Neuro-Oncology</i> , 2021 , 152, 173-182	4.8	5

219	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021 , 205, 78-85	2.5	7
218	Reply By Authors. <i>Journal of Urology</i> , 2021 , 205, 84-85	2.5	
217	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021 , 4, e2021869	10.4	23
216	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021 , 397, 695-703	4 ⁰	5 ⁰
215	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021 , 80, 693-700	10.2	10
214	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021 , 10, 1212-1221	4.8	4
213	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102971	7	4
212	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020 , 3, 530-539	6.7	14
211	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020 , 25, 422-430	5.7	5
210	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5024-5024	2.2	8
209	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 639-639	2.2	1
208	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 729-729	2.2	1
207	Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e224-e232	3.3	2
206	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e350-e359	3.3	1
205	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 559-566	2.7	1
204	Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population. <i>Canadian Urological Association Journal</i> , 2020 , 14, E499-E506	1.2	4
203	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019 , 76, 861-867	10.2	39
202	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e1181-e1184	3.3	

201	Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2019 , 33, 1650-1662	10.7	8
200	Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Current Oncology</i> , 2019 , 26, e175-e179	2.8	13
199	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. <i>American Journal of Pathology</i> , 2019 , 189, 2046-2060	5.8	1
198	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 576.e11-576.e16	2.8	0
197	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019 , 13, 343-354	1.2	8
196	Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 610-610	2.2	1
195	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 425-435.e4	3.3	9
194	Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer. <i>Kidney Cancer</i> , 2019 , 3, 213-225	0.6	2
193	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019 , 2, 643-648	6.7	19
192	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019 , 108, 69-77	7.5	20
191	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). <i>Journal of Cancer Education</i> , 2019 , 34, 14-18	1.8	
190	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2019 , 13, 166-174	1.2	7
189	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018 , 74, 309-321	10.2	40
188	The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. <i>European Radiology</i> , 2018 , 28, 2281-2290	8	21
187	Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 12.e1-12.e6	2.8	11
186	Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018 , 12, 173-180	1.2	11
185	Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer. <i>Cancer Medicine</i> , 2018 , 7, 4396-4405	4.8	25
184	Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. <i>Molecular Oncology</i> , 2018 , 12, 1673-1688	7.9	7

183	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 581-581	2.2	3
182	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 615-615	2.2	2
181	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 667-667	2.2	
180	Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. <i>Current Oncology</i> , 2018 , 25, e576-e584	2.8	14
179	Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. <i>Clinical Drug Investigation</i> , 2018 , 38, 1155-1165	3.2	4
178	Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1235-1242	2.7	3
177	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017 , 71, 204-209	10.2	52
176	CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib. <i>Cancer Imaging</i> , 2017 , 17, 4	5.6	59
175	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017 , 6, 902-909	4.0	28
174	Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature. <i>Clinical Oncology</i> , 2017 , 29, 231-238	2.8	29
173	Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 1618-1629	6.7	48
172	Platelet to white blood cell ratio predicts 30-day postoperative infectious complications in patients undergoing radical nephrectomy for renal malignancy. <i>Canadian Urological Association Journal</i> , 2017 , 11, E414-E420	1.2	15
171	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017 , 1, 41-47	0.6	9
170	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, 310-320	1.2	6
169	Effects of circadian rhythms and treatment times on the response of radiotherapy for painful bone metastases. <i>Annals of Palliative Medicine</i> , 2017 , 6, 14-25	1.7	22
168	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017 , 35, 3671-3677	2.2	77
167	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. <i>Targeted Oncology</i> , 2017 , 12, 655-661	5	10
166	Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer. <i>Quality of Life Research</i> , 2017 , 26, 2783-2791	3.7	16

165	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017 , 11, 112-117	1.2	25
164	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4514-4514	2.2	2
163	Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4574-4574 ⁴	2.2	4
162	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4594-TPS4594	2.2	12
161	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 468-468	2.2	4
160	Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 465-465	2.2	
159	Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 458-458	2.2	
158	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16078-e16078	2.2	
157	Nivolumab in the treatment of metastatic renal cell carcinoma: A cost-utility analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18331-e18331	2.2	
156	S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2016 , 33, 63-71	4.7	12
155	Isolated brain metastasis from a small renal mass. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	1
154	Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database. <i>Urology</i> , 2016 , 95, 95-102	1.6	15
153	Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2016 , 42, 763-8	3.5	9
152	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016 , 70, 358-64	10.2	112
151	The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 1097-105	3.9	60
150	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4570-4570	2.2	1
149	Objective sleep duration (SD) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 511-511	2.2	
148	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4554-4554	2.2	

147	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4510-4510	2.2	
146	Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?. <i>Canadian Urological Association Journal</i> , 2016 , 10, S252-S255	1.2	5
145	Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases?. <i>Annals of Palliative Medicine</i> , 2016 , 5, 267-279	1.7	14
144	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3655-3663	2.2	111
143	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016 , 65, 102-8	7.5	51
142	Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e79-85	3.3	59
141	Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2015 , 113, 12-9	8.7	136
140	Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 171-8	2.8	5
139	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , 2015 , 16, 293-300	21.7	229
138	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <i>Science Translational Medicine</i> , 2015 , 7, 282ra50	17.5	40
137	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1814-23	59.2	762
136	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015 , 113, 1571-80	8.7	76
135	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Molecular Therapy</i> , 2015 , 23, 1748-1758	11.7	63
134	Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. <i>European Urology</i> , 2015 , 68, 506-15	10.2	27
133	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 150-5	3.3	9
132	Dynamic contrast enhanced ultrasound for therapy monitoring. <i>European Journal of Radiology</i> , 2015 , 84, 1650-7	4.7	50
131	Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 513-22	6.1	50
130	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015 , 9, 164-70	1.2	15

129	miR-210 is a prognostic marker in clear cell renal cell carcinoma. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 136-44	5.1	49
128	Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. <i>Sleep Medicine</i> , 2015 , 16, 391-8	4.6	39
127	Effect of the timing of sunitinib administration on the predictive value of biomarkers in renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11096-11096	2.2	3
126	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4555-4555	2.2	2
125	Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 404-404	2.2	1
124	The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 424-424	2.2	1
123	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 430-430	2.2	2
122	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies 2015 , 365-384		
121	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15578-e15578	2.2	0
120	Subjective sleep problems and objective circadian disruption: Impact on outcomes in patients with metastatic colorectal cancer (MCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14584-e14584	2.2	
119	Symptoms associated with circadian rest-activity rhythm disruption in 237 patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1-1	2.2	20
118	Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. <i>European Urology</i> , 2014 , 65, 577-84	10.2	166
117	Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 760-7	2.2	290
116	Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. <i>British Journal of Cancer</i> , 2014 , 110, 1250-9	8.7	43
115	Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. <i>Molecular Cancer</i> , 2014 , 13, 101	42.1	101
114	Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014 , 66, 704-10	10.2	282
113	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e127-31	3.3	20
112	Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 480-7	2.8	66

111	Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. <i>European Urology</i> , 2014 , 65, 1086-92	10.2	56
110	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 286-96	21.7	215
109	Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. <i>Oncotarget</i> , 2014 , 5, 506-18	3.3	72
108	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , 2014 , 110, 1917-22	8.7	54
107	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. <i>British Journal of Cancer</i> , 2014 , 110, 648-55	8.7	57
106	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. <i>Annals of Oncology</i> , 2014 , 25, 149-54	10.3	99
105	Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer. <i>Investigative Radiology</i> , 2014 , 49, 116-23	10.1	16
104	The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2014 , 8, 258-64	2.6	13
103	Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. <i>Journal of Neurosurgery: Spine</i> , 2014 , 21, 711-8	2.8	100
102	Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 354-8	3.3	20
101	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4576-4576	2.2	2
100	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 396-396	2.2	7
99	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 398-398	2.2	6
98	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway targeted therapy and one prior mTOR inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 473-473	2.2	1
97	Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia (CLL) patients: A proof of principle pilot study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22220-e22220		
96	Patient-reported sleep disruption as an independent prognostic factor for overall survival in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 410-410	2.2	
95	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013 , 8, 203-209	5	45
94	miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. <i>Carcinogenesis</i> , 2013 , 34, 2231-9	4.6	128

93	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013 , 119, 2999-3006	6.4	144
92	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology, The</i> , 2013 , 14, 141-8	21.7	598
91	Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. <i>Journal of Oncology Practice</i> , 2013 , 9, e262-7	3.1	31
90	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013 , 7, 319-23	1.2	23
89	Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. <i>Canadian Urological Association Journal</i> , 2013 , 7, 238-43	1.2	6
88	Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 132-44	7.6	56
87	Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. <i>Cancer</i> , 2013 , 119, 2564-73	6.4	34
86	Contrasting the vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 378-378	2.2	3
85	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 394-394	2.2	1
84	Suppression of tumor progression and metastasis in renal cell carcinoma by miR-192, miR-194, and miR-215.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 385-385	2.2	1
83	Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 396-396	2.2	
82	Relative quantification of protein expression in metastatic renal cell carcinoma using iTRAQ LC-MS/MS analysis reveals galectin-1 as a potential prognostic marker and therapeutic target.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 412-412	2.2	
81	Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. <i>Tumor Biology</i> , 2012 , 33, 131-40	2.9	55
80	An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012 , 48, 324-32	7.5	70
79	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology, The</i> , 2012 , 13, 927-35	21.7	104
78	The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. <i>Journal of Molecular Diagnostics</i> , 2012 , 14, 385-92	5.1	88
77	Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. <i>Current Oncology</i> , 2012 , 19, 202-8	2.8	25
76	Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2012 , 131, 2684-92	7.5	76

75	Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. <i>Annals of Oncology</i> , 2012 , 23, 3110-3116	10.3	73
74	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. <i>Annals of Oncology</i> , 2012 , 23, 1549-55	10.3	108
73	Management of kidney cancer: canadian kidney cancer forum consensus update 2011. <i>Canadian Urological Association Journal</i> , 2012 , 6, 16-22	1.2	18
72	Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 6023-31	12.9	63
71	Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10622-10622	2.2	1
70	Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 464-464	2.2	6
69	A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 353-353	2.2	3
68	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 387-387	2.2	5
67	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies 2012 , 265-283		
66	Use of miRNA profiling in metastatic renal cell carcinoma to reveal a tumor suppressor effect for mir-215.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4633-4633	2.2	
65	Preoperative stereotactic body radiotherapy to a skull renal cell metastasis: an alternative to preoperative embolization?. <i>Journal of Palliative Medicine</i> , 2011 , 14, 157-60	2.2	1
64	miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. <i>Journal of Urology</i> , 2011 , 186, 1077-83	2.5	163
63	Improved flow measurement using microbubble contrast agents and disruption-replenishment: clinical application to tumour monitoring. <i>Ultrasound in Medicine and Biology</i> , 2011 , 37, 1210-21	3.5	32
62	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011 , 117, 501-9	6.4	110
61	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011 , 117, 2637-42	6.4	64
60	Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). <i>Chronobiology International</i> , 2011 , 28, 586-600	3.6	29
59	Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. <i>Radiology</i> , 2011 , 260, 581-90	20.5	107
58	Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2011 , 22, 145-148	10.3	44

57	miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. <i>British Journal of Cancer</i> , 2011 , 105, 1741-9	8.7	141
56	Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. <i>Oncologist</i> , 2011 , 16, 543-53	5.7	65
55	Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4003-4003	2.2	53
54	External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4560-4560	2.2	5
53	Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4627-4627	2.2	6
52	An individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.. <i>Journal of Clinical Oncology</i> , 2011 , 29, e15149-e15149	2.2	2
51	Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 318-318	2.2	3
50	Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. <i>Current Oncology</i> , 2011 , 18 Suppl 2, S11-9	2.8	13
49	Effect of an individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 356-356	2.2	2
48	Chronotherapy and the molecular clock: Clinical implications in oncology. <i>Advanced Drug Delivery Reviews</i> , 2010 , 62, 979-1001	18.5	118
47	A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4523-4523	2.2	6
46	Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. <i>Cancer Research</i> , 2009 , 69, 4700-7	10.1	162
45	Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. <i>Cancer Cell</i> , 2009 , 15, 232-9	24.3	1455
44	Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 166-72	4	76
43	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3584-90	2.2	1729
42	From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. <i>Molecular Cancer</i> , 2009 , 8, 20	42.1	53
41	Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. <i>Integrative Cancer Therapies</i> , 2009 , 8, 361-70	3	38
40	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , 2009 , 10, 757-63	21.7	478

39	A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 134-9	3.8	5
38	Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 11032-11037	2.2	74
37	Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU-leucovorin as first-line chemotherapy for metastatic colorectal cancer (MCC). <i>Journal of Clinical Oncology</i> , 2008 , 26, 11032-11032	2.2	7
36	Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCR): A PMH phase II consortium trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4027-4027	2.2	16
35	Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5094-5094	2.2	7
34	Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2008 , 26, 5114-5114	2.2	18
33	Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2008 , 26, 5124-5124	2.2	13
32	Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. <i>Canadian Urological Association Journal</i> , 2007 , 1, S41-54	1.2	83
31	A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 60, 135-41	3.5	33
30	Diurnal protein expression in blood revealed by high throughput mass spectrometry proteomics and implications for translational medicine and body time of day. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007 , 293, R1430-7	3.2	26
29	Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx). <i>Journal of Clinical Oncology</i> , 2007 , 25, 2507-2507	2.2	4
28	Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2569-77	2.2	150
27	Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). <i>Investigational New Drugs</i> , 2005 , 23, 51-6	4.3	
26	A recent illustration of some essentials of circadian chronotherapy study design. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2971-2; author reply 2972	2.2	12
25	Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 1487-95	4	4
24	It is time for chronotherapy!. <i>Pathologie Et Biologie</i> , 2003 , 51, 197-200		8
23	Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1524-9	2.2	33
22	Low-dose ultraviolet B rays alter the mRNA expression of the circadian clock genes in cultured human keratinocytes. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 1220-3	4.3	49

21	Rhythms in human gastrointestinal mucosa and skin. <i>Chronobiology International</i> , 2002 , 19, 129-40	3.6	71
20	Postoperative concurrent chronomodulated 5-fluorouracil/leucovorin infusion and pelvic radiotherapy for squamous cell carcinoma of the ovary arising from mature cystic teratoma. <i>International Journal of Gynecological Cancer</i> , 2001 , 11, 418-21	3.5	8
19	Are medical oncologists biased in their treatment of the large woman with breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2001 , 66, 123-33	4.4	57
18	Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. <i>American Journal of Pathology</i> , 2001 , 158, 1793-801	5.8	298
17	Irinotecan-associated pulmonary toxicity. <i>Anti-Cancer Drugs</i> , 2000 , 11, 709-13	2.4	31
16	Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. <i>Progress in Cell Cycle Research</i> , 2000 , 4, 193-206		79
15	Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. <i>Acta Oncologica</i> , 1999 , 38, 255-9	3.2	16
14	Circadian variation in the expression of cell-cycle proteins in human oral epithelium. <i>American Journal of Pathology</i> , 1999 , 154, 613-22	5.8	136
13	Scoring oral mucositis. <i>Oral Oncology</i> , 1998 , 34, 63-71	4.4	92
12	Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 537-42	2.7	0
11	Menstrual cycle chronobiology: is it important in breast cancer screening and therapy?. <i>Lancet, The</i> , 1996 , 347, 345-6	4.0	5
10	Chronobiology. Implications for cancer chemotherapy. <i>Acta Oncologica</i> , 1995 , 34, 615-24	3.2	9
9	Steroid-responsive interstitial lung disease in patients receiving 2Pdeoxy-5-fluorouridine-infusion chemotherapy. A report of three cases. <i>Cancer</i> , 1995 , 75, 2558-64	6.4	2
8	Clinical cancer chronotherapy trials: a review. <i>The Journal of Infusional Chemotherapy</i> , 1995 , 5, 31-7		0
7	Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer. <i>The Journal of Infusional Chemotherapy</i> , 1995 , 5, 82-8		
6	Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. <i>In Vivo</i> , 1995 , 9, 557-64	2.3	3
5	Adjuvant therapy with fluorouracil and levamisole and liver ultrasound mimicking liver metastases. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1335-6	2.2	
4	Reply to letter by M. Smolensky and L. T. Campos. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 34, 271-272	3.5	

3	Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 33, 221-8	3.5	30
2	Circadian cancer therapy. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1403-17	2.2	87
1	TimeTeller: a New Tool for Precision Circadian Medicine and Cancer Prognosis		8